Missing Selectivity of Targeted 4β-Phorbol Prodrugs Expected to be Potential Chemotherapeutics

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Delivery

Background:

• Targeting cancer tissues specifically is crucial for effective chemotherapy.
• Proteases such as prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) are upregulated in certain cancers.
• Prodrug strategies aim to release active cytotoxic agents selectively at the tumor site.

Purpose of the Study:

• To design and synthesize novel 4β-phorbol ester prodrugs conjugated with PSA and PSMA substrates.
• To investigate the cellular uptake, activation, and cytotoxicity of these prodrugs in cancer cells.
• To evaluate the potential for targeted delivery and selective cancer cell killing.

Main Methods:

• Synthesis of 4β-phorbol esters from Croton tiglium.
• Solid-phase peptide synthesis of PSA and PSMA substrate sequences.
• Conjugation of 4β-phorbol esters to peptide substrates.
• Cellular assays to assess protein kinase C (PKC) activation and cell viability.

Main Results:

• Prodrugs were successfully synthesized and conjugated.
• Cellular assays demonstrated activation of PKC by the prodrugs.
• The prodrugs exhibited efficient killing of both peptidase-positive and peptidase-negative cells.
• No significant selectivity for cancer cells expressing the target proteases was observed.

Conclusions:

• The developed 4β-phorbol ester prodrugs can activate PKC and kill cancer cells.
• The hydrophilic peptide moiety did not confer selectivity for protease-expressing cancer cells.
• Further optimization is needed to achieve targeted delivery and selective cytotoxicity.